Literature DB >> 21241697

Increase in CIP2A expression is associated with doxorubicin resistance.

Yeon A Choi1, Jeong Su Park, Mi Young Park, Ki Sook Oh, Myung Sok Lee, Jong-Seok Lim, Keun Il Kim, Kun-yong Kim, Junhye Kwon, Do Young Yoon, Eun-Yi Moon, Young Yang.   

Abstract

The cancerous inhibitor of protein phosphatase 2A (CIP2A) increases the migration and metastasis of various cancer cells. Overexpression of CIP2A has been shown to increase the proliferation of MDA-MB-231 cells. We thus assessed whether CIP2A expression is associated with sensitivity to doxorubicin. MDA-MB-231 cells showed an increase in CIP2A expression after treatment with doxorubicin, while MCF-7 cells showed a decrease in CIP2A expression. The overexpression of CIP2A in MCF-7 cells overcame the inhibition of cell proliferation in response to doxorubicin treatment. CIP2A expression was not affected by wild-type or mutant p53. However, mutant p53 blocked doxorubicin-mediated CIP2A down-regulation in HCT116 cells. As a regulation mechanism of doxorubicin-mediated CIP2A expression, we showed that phosphorylated Akt was involved in the suppression of CIP2A expression.
Copyright © 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21241697     DOI: 10.1016/j.febslet.2011.01.018

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  28 in total

1.  Knockdown of CIP2A sensitizes ovarian cancer cells to cisplatin: an in vitro study.

Authors:  Xiaoli Zhang; Bin Xu; Chuanying Sun; Liming Wang; Xia Miao
Journal:  Int J Clin Exp Med       Date:  2015-09-15

2.  Cellular localization of CIP2A determines its prognostic impact in superficial spreading and nodular melanoma.

Authors:  Vivi Ann Flørenes; Elisabeth Emilsen; Hiep Phuc Dong; Mette Førsund; Ruth Holm; Ana Slipicevic
Journal:  Cancer Med       Date:  2015-02-07       Impact factor: 4.452

Review 3.  Targeting PP2A in cancer: Combination therapies.

Authors:  Sahar Mazhar; Sarah E Taylor; Jaya Sangodkar; Goutham Narla
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-09-01       Impact factor: 4.739

4.  CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.

Authors:  Yijun Xue; Gengqing Wu; Xiaoning Wang; Xiaofeng Zou; Guoxi Zhang; Rihai Xiao; Yuanhu Yuan; Dazhi Long; Jun Yang; Yuting Wu; Hui Xu; Folin Liu; Min Liu
Journal:  Med Oncol       Date:  2012-12-30       Impact factor: 3.064

5.  Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.

Authors:  Jinming Huang; Jiaoyuan Jia; Qiang Tong; Jun Liu; Jun Qiu; Rong Sun; Lixin Yao; Chun Yang
Journal:  Tumour Biol       Date:  2014-11-07

6.  Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.

Authors:  Ae Lee Jeong; Sunyi Lee; Jeong Su Park; Sora Han; Chang-Young Jang; Jong-Seok Lim; Myung Sok Lee; Young Yang
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

7.  Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.

Authors:  H Liu; H Qiu; Y Song; Y Liu; H Wang; M Lu; M Deng; Y Gu; J Yin; K Luo; Z Zhang; X Jia; G Zheng; Z He
Journal:  Oncogene       Date:  2016-10-03       Impact factor: 9.867

8.  Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer.

Authors:  Zi Liu; Liang Ma; Zhe-Sheng Wen; Zheng Hu; Fu-Qun Wu; Wei Li; Jinsong Liu; Guang-Biao Zhou
Journal:  Carcinogenesis       Date:  2013-11-30       Impact factor: 4.944

9.  Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.

Authors:  Chun-Yu Liu; Chung-Wai Shiau; Hsin-Yu Kuo; Hsiang-Po Huang; Ming-Huang Chen; Cheng-Hwai Tzeng; Kuen-Feng Chen
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

10.  Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.

Authors:  L Wei; W Qu; J Sun; X Wang; L Lv; L Xie; X Song
Journal:  Cancer Gene Ther       Date:  2014-05-30       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.